Immunomodulation of allergic sinonasal disease

American Journal of Rhinology and Allergy

Volumn 27, Issue SUPPL.1, 2013, Pages

  Settipane, Russell A ^a   Peters, Anju T ^b   Borish, Larry ^c  

^a BROWN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; INTERLEUKIN 10; OMALIZUMAB; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ALLERGY IMMUNOTHERAPY; ANAPHYLAXIS; ARTICLE; B LYMPHOCYTE; CHRONIC RHINOSINUSITIS; DRUG ADMINISTRATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAY FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; TREATMENT DURATION; ANIMAL; DESENSITIZATION; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; IMMUNOLOGY; METHODOLOGY; PARANASAL SINUS; PATHOLOGY; RESPIRATORY TRACT ALLERGY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; UNITED STATES; DRUG EFFECTS; PROCEDURES; RESPIRATORY HYPERSENSITIVITY; TRENDS;

ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIBODIES, MONOCLONAL; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; IMMUNOMODULATION; INJECTIONS, SUBCUTANEOUS; PARANASAL SINUSES; RESPIRATORY HYPERSENSITIVITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84878239878     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2013.27.3930     Document Type: Article

References (54)

1. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 127(suppl): S1-S55, 2011.
2. Wise SK, and Schlosser RJ. Subcutaneous and sublingual immunotherapy for allergic rhinitis: What is the evidence? Am J Rhinol Allergy 26:18-22, 2012.
3. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131:110-116.e1, 2013.
4. Shah R, and Grammer LC. An overview of allergens. Allergy Asthma Proc 33(suppl 1):S2-S5, 2012.
5. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008.
6. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013 Mar 13 DOI: 10.1016/j.jaci.2013.01.049. [Epub ahead of print].
7. Larenas Linnemann DE. One hundred years of immunotherapy: review of the first landmark studies. Allergy Asthma Proc 33:122-128, 2012.
8. Settipane RA, and Schwindt C. Allergic rhinitis. Am J Rhinol Allergy 27:S52-S55, 2013.
9. Carr TF, and Saltoun CA. Skin testing in allergy. Allergy Asthma Proc 33(Suppl 1):S6-8, 2012.
10. Makhija M, and O'Gorman MR. Common in vitro tests for allergy and immunology. Allergy Asthma Proc 33(Suppl 1):S108-S111, 2012.
11. Settipane RA, Borish L, and Peters AT. Determining the role of allergy in sinonasal disease. Am J Rhinol Allergy 27:S56-S58, 2013.
12. Settipane RA, Peters AT, and Chandra R. Chronic rhinosinusitis. Am J Rhinol Allergy 27:S11-S15, 2013.
13. Settipane RA, Peters AT, and Chiu AG. Nasal polyps. Am J Rhinol Allergy 27:S20-S25, 2013.
14. Kennedy JL, and Borish L. Chronic sinusitis pathophysiology: The role of allergy. Am J Rhinol Allergy DOI: 10.2500/ajra.2013.27.3906 [Epub ahead of print date April 18, 2013].
15. Fokkens WJ, Lund VJ, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl 23:1-298, 2012.
16. Nathan RA, Santilli J, Rockwell W, and Glassheim J. Effective of immunotherapy for recurring sinusitis associated with allergic rhinitis as assessed by Sinusitis Outcomes Questionnaire. Ann Allergy Asthma Immunol 92:668-672, 2004.
17. Smith AM, Rezvani M, and Bernstein JA. Is response to allergen immunotherapy a good phenotypic marker for differentiating between allergic rhinitis and mixed rhinitis? Allergy Asthma Proc 32:49-54, 2011.
18. Frew A. Allergen immunotherapy. J Allergy Clin Immunol 125:S306-S313, 2010.
19. Grammer LC, and Harris KE. Principles of immunologic management of allergic diseases due to extrinsic antigens. In Patterson's Allergic Diseases, 7th ed. Grammer LC, and Greenberger PA (Eds). Philadelphia, PA: Lippincott, Williams & Wilkins, 187-196, 2009.
20. Georgy MS, and Saltoun CA. Allergen immunotherapy: Definition, indication, and reactions. Allergy Asthma Proc 33(suppl 1):S9-S11, 2012.
21. Akdis M, and Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119:780-791, 2007.
22. Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and metaanalysis. Clin Exp Allergy 41:1263-1272, 2011.
23. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475, 1999.
24. Bernstein DI, Wanner M, Borish L, et al. Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelveyear survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 113:1129-1136, 2004.
25. Calabria CW, Stolfi A, and Tankersley MS. The REPEAT study: Recognizing and evaluation periodic local reactions in allergen immunotherapy and associated systemic reactions. Ann Allergy Asthma Immunol 106:49, 2011.
26. Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 99:82-86, 2007.
27. Greenberger PA, and Ditto AM. Anaphylaxis. Allergy Asthma Proc 33(suppl 1):S80-S83, 2012.
28. Lieberman P. The risk and management of anaphylaxis in the setting of immunotherapy. Am J Rhinol Allergy 26:469-474, 2012.
29. Phillips JF, Lockey RF, Fox RW, et al. Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine. Allergy Asthma Proc 32:288-294, 2011.
30. Wallace DV. Anaphylaxis in the allergist's office: Preparing your office and staff for medical emergencies. Allergy Asthma Proc 34: 120-131, 2013.
31. Hankin CS, Cox L, and Bronstone A. The health economics of allergen immunotherapy. Immunol Allergy Clin North Am 31:325-341, 2011.
32. Hankin CS, Cox L, Bronstone A, et al. AIT: Reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol 131:1084-1091, 2013.
33. DuBuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 32:239-247, 2011.
34. Cox L. Accelerated immunotherapy schedules: Review of efficacy and safety. Ann Allergy Asthma Immunol 97:126-137, 2006.
35. Guida G, Boita M, Scirelli T, et al. Innate and lymphocytic response of birch-allergic patients before and after sublingual immunotherapy. Allergy Asthma Proc 33:411-415, 2012.
36. Nayak AS, Atiee GJ, Dige E, et al. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy Asthma Proc 33:404-410, 2012.
37. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass AIT tablets in North American children and adolescents. J Allergy Clin Immunol 127:64-71, 71.e1-4, 2011.
38. Radulovic S, Wilson D, Calderon M, and Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66:740-752, 2011.
39. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. J Allergy Clin Immunol 126:969-975, 2010.
40. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: A systematic review. JAMA 309:1278-1288, 2013.
41. Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. J Allergy Clin Immunol 130:1097-1107.e2, 2012.
42. Genentech, Inc. XOLAIR prescribing information. South San Francisco, CA; 2007. Last revision July, 2010.
43. Soresi S, and Togias A. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc 27:S15-S23, 2006.
44. Prussin C, Griffith D, Boesel K, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 112:1147-1154, 2003.
45. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155:1828-1834, 1997.
46. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106:253-259, 2000.
47. Nayak A, Casale T, Miller SD, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 24:323-329, 2003.
48. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91:160-167, 2003.
49. Berger WE. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody. Allergy Asthma Proc 27:S29-S32, 2006.
50. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109:274-280, 2002.
51. Pinto JM, Mehta N, DiTineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48:318-324, 2010.
52. Cox L, Lieberman P, Wallace D, et al. American Academy of Allergy Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 128:210-212, 2011.
53. Limb SL, Starke PR, Lee CE and Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 120:1378-1381, 2007.
54. Busse W, Buhl R, Vidaurre CF, et al. Omalizumab and the risk of malignancy: Results from a pooled analysis. J Allergy Clin Immunol 128:983-989, 2012.